Kawachinagano

Researchers are evaluating the safety and effects of a study medicine called PF-07275315 for treating adults with moderate-to-severe asthma that is not well controlled. This condition makes breathing difficult and affects quality of life. The study is a Phase 2, randomized, double-blind, placebo-controlled trial aiming to determine if PF-07275315 is safe and effective for this group. Participants will receive either PF-07275315 or a placebo through multiple subcutaneous injections administered in the clinic over 12 weeks. The study compares these two groups to assess treatment responses. The trial includes a total of 9 clinic visits and lasts about 7.5 months for each participant. During the study, participants will undergo various assessments including lung function tests to measure forced expiratory volume in 1 second (FEV1), safety monitoring through adverse event tracking, laboratory tests, vital sign checks, and electrocardiograms. These evaluations occur from baseline through 24 weeks to observe changes and treatment tolerability.

Researchers are evaluating how the study medicine PF-06823859 (dazukibart) works in adults with active idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM). These rare diseases cause muscle inflammation that weakens muscles important for movement, and DM may also cause a characteristic skin rash. The study aims to understand the safety and effectiveness of dazukibart compared to placebo in this patient group. Participants will receive either the study medicine or a placebo, both given as intravenous (IV) infusions lasting about 1 hour. These infusions will be administered every 4 weeks from the first day up to Week 48 at the study site. The study includes a total duration of about 13 months with 15 visits to the study site for treatment and monitoring. During the study, participants will be monitored through regular visits where researchers will assess their health and response to treatment. The main outcome measured is the moderate change in the Total Improvement Score (TIS) at 24 weeks for sites outside the United States and at 52 weeks for sites within the United States. Safety and other health evaluations will be conducted throughout the study to understand how participants respond to the study medicine compared to placebo.

Researchers are evaluating an experimental drug called REGN7508, a Factor XI monoclonal antibody, to prevent Venous Thromboembolism (VTE) after elective, unilateral total knee replacement surgery in adults. The study is a Phase 3, multicenter, randomized, open-label trial comparing REGN7508 with Apixaban and Enoxaparin, two other blood-thinning medications, as well as a placebo. The goal is to assess how well REGN7508 works to stop VTE and related conditions following knee surgery, along with monitoring possible side effects, drug levels in the blood, and the body's immune response to the drug.